ALK and lung carcinoma: Finally, the fourth subgroup comprises the rest of the patients with none of the above mutational biomarkers but with other possible mutated biomarkers, for which the best treatment is Crizotinib -an ALK and MAPK inhibitor- approved by the FDA for lung cancer.